Cargando…

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

Ursodeoxycholic acid (UDCA) is the first-line therapy used for the treatment of PBC. In recent years, new pharmacological agents have been proposed for PBC therapy to cure UDCA-non-responders. Obeticholic acid (OCA) is registered in many countries for PBC, and fibrates also seem to be effective in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Floreani, Annarosa, Gabbia, Daniela, De Martin, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405864/ https://www.ncbi.nlm.nih.gov/pubmed/36009580 http://dx.doi.org/10.3390/biomedicines10082033

Ejemplares similares

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa
Publicado: (2020)

The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report
por: Del Ross, Teresa, et al.
Publicado: (2016)

Update on Emerging Treatment Options for Primary Biliary Cholangitis
por: Aguilar, Maria T, et al.
Publicado: (2020)

Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study
por: Turco, Matteo, et al.
Publicado: (2018)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis
por: Cazzagon, Nora, et al.
Publicado: (2021)

The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update
por: Hitomi, Yuki, et al.
Publicado: (2023)

New treatments/targets for primary biliary cholangitis
por: Corpechot, Christophe, et al.
Publicado: (2019)

Primary biliary cholangitis: Epidemiology, prognosis, and treatment
por: Trivella, Juan, et al.
Publicado: (2023)

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
por: Harms, Maren H., et al.
Publicado: (2020)

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
por: Barba Bernal, Romelia, et al.
Publicado: (2023)

Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis
por: Overi, Diletta, et al.
Publicado: (2022)

Recent advances in the diagnosis and treatment of primary biliary cholangitis
por: Huang, Ying-Qiu
Publicado: (2016)

The Role of Epigenetics in Primary Biliary Cholangitis
por: Gerussi, Alessio, et al.
Publicado: (2022)

Current understanding of primary biliary cholangitis
por: Tanaka, Atsushi
Publicado: (2021)

Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update
por: Bowlus, Christopher L., et al.
Publicado: (2016)

Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
por: Trivedi, Hirsh D, et al.
Publicado: (2020)

Biomarkers for primary biliary cholangitis: current perspectives
por: Kouroumalis, Elias, et al.
Publicado: (2018)

Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches
por: Galoosian, Artin, et al.
Publicado: (2020)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis
por: Joshita, Satoru, et al.
Publicado: (2017)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

An update on treatment options for primary sclerosing cholangitis
por: Iravani, Shahrokh, et al.
Publicado: (2020)

Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis
por: Reshetnyak, Vasiliy I., et al.
Publicado: (2022)

Role of autoantibodies in the clinical management of primary biliary cholangitis
por: Rigopoulou, Eirini I, et al.
Publicado: (2023)

Animal models of primary biliary cholangitis: status and challenges
por: Wang, Xu, et al.
Publicado: (2023)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

COVID-19 and Autoimmune Liver Diseases
por: Floreani, Annarosa, et al.
Publicado: (2022)

Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review
por: Smith, Helen T., et al.
Publicado: (2023)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
por: Colapietro, Francesca, et al.
Publicado: (2023)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Primary biliary cholangitis: pathogenic mechanisms
por: Prieto, Jesús, et al.
Publicado: (2021)

Predicting Risk in Primary Biliary Cholangitis
por: Cho, Eun Ju
Publicado: (2023)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_krddmkppnarcv22veld0070ovp